Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2023 | Promising therapeutic options emerging in hemophilia

Katharina Holstein • 25 Jun 2023
ISTH 2023
Hemophilia Non-Malignant Antibodies Efanesoctocog alfa Fitusiran

Katharina Holstein, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly discusses promising agents emerging in hemophilia treatment, including fitusiran and efanesoctocog alfa. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Grants for research or clinical studies (to institution): Bayer, CSL Behring, NovoNordisk, Pfizer, Sobi
Honoraria for lectures or consultancy (to person):
Bayer, Biotest, Chugai, CSL Behring, LFB, Novo Nordisk, Pfizer, Roche, Sobi, Takeda

More from Katharina Holstein

1:46
Unmet needs in hemophilia B: treating patients who develop inhibitors
Katharina Holstein • 25 Jun 2023

Related Videos

2:46
Morbidity and mortality data from the UK National Haemoglobinopathy Registry
Farrukh Shah • 30 Apr 2024
3:47
The modeling of HbS dynamics following red cell exchange transfusion to improve patient care
Richard Salisbury • 28 Apr 2024
2:41
A trial investigating enoxaparin vs placebo as thromboprophylaxis in hospitalized older patients
Gregoire Le Gal • 29 Apr 2024
1:09
Improving the mental health and psychological resilience of patients with SCD
Marsha Treadwell • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals